HK Stock Market Move | ABISKO-B(02256) rose more than 5% and Yuyi Pharmaceuticals announced that the oral small molecule pan-KRAS inhibitor ABSK211 has received IND approval from the US FDA.

ABBISKO-B (02256) rose more than 5%, as of the time of writing, it increased by 5.53% to 11.25 Hong Kong dollars, with a turnover of 2.5452 million Hong Kong dollars. On the news front, recently ABBISKO-B announced that its subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Medicine) announced that the company's orally administered, highly potent, highly selective small molecule pan-KRAS inhibitor ABSK211 for the treatment of patients with advanced solid tumors carrying KRAS gene mutations has received approval for Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA). This announcement was voluntarily made by the company. The group cannot guarantee that ABSK211 will ultimately be successfully approved for market. ABSK211 is a novel orally administered, highly potent, highly selective small molecule pan-KRAS inhibitor independently developed by Heyu Medicine, aiming to cover a variety of KRAS gene mutations, including common KRAS mutation subtypes and specific amplification states. Preclinical research results have shown that ABSK211 exhibits positive anti-tumor activity and good selectivity in both monotherapy and combination therapy scenarios, providing new treatment options for patients with solid tumors carrying KRAS gene mutations.